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Abstract 
Aims: Tumor associated macrophages (TAMs) play a critical role in the initiation and progression 
of breast cancer. However, their prognostic significance in the molecular subtype of basal-like breast 
cancer (BLBC) is poorly understood. The aim of this study was to investigate the extent and 
patterns of TAMs in BLBC and their associations with clinicopathological features and patient 
survival. 
Methods and Results: We evaluated TAMs in 200 cases of BLBC by immunohistochemistry using 
the M2 macrophage marker CD163 and the pan-macrophage marker CD68 in tumor nest and 
stroma, and assessed their prognostic significance. 
The study demonstrated that infiltration of CD163+ and CD68+ macrophages in tumor stroma was 
of clinical relevance in BLBC, but not those in tumor nest. Increased stromal infiltration of CD68+ or 
CD163+ macrophages correlated with larger tumor size, higher histological grade, higher 5-year 
recurrence and 5-year breast cancer mortality. Although both of CD68+ and CD163+ macrophages 
in tumor stroma were associated with poor recurrence-free survival (RFS) and overall survival (OS), 
multivariate analysis demonstrated that only CD163+ macrophage was an independent predictor of 
RFS and OS. 
Conclusions: Our results highlight the prognostic importance of TAMs’ location in BLBC. CD163, 
a highly specific biomarker for M2 macrophages, is an independent prognostic marker for BLBC 
patients, and may serve as an indicator or potential target of macrophage-centred therapeutic 
strategies. 
Key words: Tumor associated macrophages, CD163, CD68, Basal-like breast cancer, Prognosis 
Introduction 
Inflammatory cells are a key component of the 
tumor microenvironment and influence the growth 
and progression of tumor [1, 2]. Tumor-associated 
macrophages (TAMs) constitute a major component 
of leukocyte population infiltrating tumors of the 
breast [3, 4]. Numerous studies have demonstrated 
that TAMs enhance tumor invasion, migration and 
angiogenesis in many solid tumors including breast 
cancer [5-7], however, with the deepening of the 
research, controversial conclusions have always been 
made. 
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Accumulating evidences suggests that 
macrophages are not a homogenous population. 
Thus, it should be more prudent to get a conclusion in 
the relationship between TAMs heterogeneity and 
breast cancer heterogeneity. Breast cancer is one of the 
few types of tumor that molecular classification has 
been successfully used in individualized treatment 
design, which can significantly improve disease 
specific patient survival [8]. Triple-negative breast 
cancer is negative for hormone receptors (HR) of 
estrogen (ER) and progesterone (PR), and human 
epidermal growth factor receptor-2 (HER2), and thus 
cannot benefit from the targeted treatment, such as 
Tamoxifen, Anastrozole, and Trastuzumab [9, 10]. A 
number of independent studies have demonstrated 
the correlation of TAM with ER-negativity, 
PR-negativity, and high mitotic rate [11-20]. Medrek C 
et al. found intensity of macrophage infiltration in 
tumor stoma inversely correlated with luminal A 
phenotype and positively correlated with 
triple-negative/basal-like phenotype of breast cancer 
[20]. We noticed that the association of TAMs with 
poor outcome was not always correct for HR/HER 
status or molecular subtypes. Thus, the prognostic 
significance of TAMs in breast cancer should be 
reassessed in larger cohorts separately depending on 
molecular classifications. The majority of 
triple-negative cancers are of basal-like phenotype 
[21] which has the poorest prognosis. Basal-like breast 
cancer (BLBC) defined by Cheang et al. [22] was 
adopted in our study. 
Macrophages exhibit striking plasticity and 
change their physiology according to environmental 
cues. This lead to heterogeneous populations of 
specific subsets with distinct phenotype, polarization 
and functions [23, 24]. TAMs can be identified as two 
distinct states of polarized activation: the 
anti-tumor/pro-inflammatory M1 macrophages and 
the pro-tumoral/anti-inflammatory M2 macrophages 
[25, 26]. M1 macrophages are characterized by 
expressing high levels of HLADR, inducible nitric 
oxide synthase (iNOS) and tumor necrosis factor-α 
(TNF-α), and by high microbicidal and tumoricidal 
activity, which are associated with a better prognosis 
[27]. In contrast, M2 macrophages typically express 
arginase 1 (ARG1) , high levels of scavenging, 
mannose and galactose receptors, high levels of 
cytokines and chemokines that support their 
pro-tumoral functions [28]. M2 macrophages are 
involved in suppression of adaptive immunity, 
stimulation of angiogenesis, promotion of matrix 
remodeling and tumor invasion and migration. 
In some cases, CD68+ TAMs were considered as 
a prognostic predictor in breast cancer. However, in 
some multivariate analyses, CD68 was not confirmed 
to be independent predictor of survival [14, 15, 17]. 
The most probable cause is both M1 and M2 
macrophage can be stained by anti-CD68 Abs. CD163, 
the haemoglobin scavenger receptor, is typically 
expressed by TAMs and up-regulated in progressing 
neoplasms. In many studies, CD163 is regarded as a 
highly specific marker for M2-like polarized 
macrophages [29-32]. Some studies proved that 
CD163+ TAMs was more closely related to 
unfavorable clinicopathological features in breast 
cancer [20]. However, to our knowledge no paper has 
reported the presence and prognostic significance of 
CD68+ and CD163+ macrophages in the basal-like 
subset of breast cancer by molecular classification. 
Therefore, the aim of this study was to investigated 
the extent of infiltration and distribution patterns of 
macrophages in BLBC, to compare TAMs labeled by 
CD163 with those identified by the more frequently 
used pan-macrophage marker CD68, and to 
determine their association with clinicopathological 
features and prognostic value in BLBC. 
Materials and Methods 
Patients 
We included 200 cases of BLBC from 1,971 
contiguous cases of invasive breast cancer diagnosed 
at the Department of Pathology, Tianjin Medical 
University Cancer Hospital (Tianjin, China), between 
April 2006 and December 2007. Neoadjuvant therapy 
(NAT) will seriously affect the immune cells including 
TAMs in the tumor microenvironment, so all the 
patients selected in this study are BLBC patients who 
did not receive NAT before surgery. And we chose 
BLBCs that contain only IDC-NOS, which have 
relatively uniform molecular and pathological 
features (CONSORT diagram, Fig. 1). The patients 
were followed up for 12–86 months (median, 66 
months), and the range of the patients age at the time 
of diagnosis was 26-81 years (median, 51 years). 
During the follow-up, 42 (21%) patients died of 
cancer, and 66 patients (33%) developed a breast 
cancer recurrence, included 9 (4.5%) with local or 
regional tumor recurrence and 57 (28.5%) with distant 
metastasis. All the patients underwent modified 
radical mastectomy or breast-conserving surgery with 
axillary lymph node dissection. Postoperatively, all 
the patients received adjuvant chemotherapy and 156 
(78%) received radiation therapy. All patients signed 
an informed consent form for the use of their 
biological tissues in the study. The study was 
reviewed and approved by the Institutional Ethics 
Committee of Tianjin Medical University Cancer 
Institute and Hospital, Tianjin, China (No. bc2015005). 
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Fig. 1. CONSORT diagram. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded serial tissue 
sections of full block-face tissue from surgical 
specimen of each case were selected for CD68+ and 
CD163+ immunohistochemical stains using standard 
procedures. Briefly, 4µm tissue sections were 
subsequently dewaxed and rehydrated using xylene 
and graded alcohol washes. Antigen retrieval was 
performed at 121oC for 2 min, using citrate buffer, pH 
6.0. After serial blocking with hydrogen peroxide and 
normal goat serum, the sections were incubated with 
primary polyclonal antibody against CD68 (Abcam, 
ab213096, monoclonal [KP1], 0.5µg/ml) and CD163 
(Abcam, ab74604, monoclonal [10D6]) for 30 min at 
room temperature. Then, the sections were 
sequentially incubated with biotinylated goat 
anti-mouse immunoglobulin and peroxidase- 
conjugated streptavidin. 
TAMs were scored as the infiltration density of 
CD68+ or CD163+ cells with a monocyte/macrophage 
morphology with oval or rounded nuclei that showed 
strong membranous or cytoplasmic staining. In this 
study, TAMs in tumor nest (TN) is defined as the 
intraepithelial tumor-infiltrating macrophages. The 
definition of ‘tumor stroma (TS)’ in this study is the 
fibrous tissue surrounding tumor nest (Fig. 2); the 
lymphoid infiltrates surrounding the tumor bed are 
excluded. TAMs were evaluated by adapting the 
reported hotspot quantitative method.[17, 18, 33-36] 
The entire stained section was first scanned at low 
magnification (×100) to identify the hotspot areas (five 
areas of TN and five areas of TS) with most abundant 
macrophages. The average count of macrophages in 
all five areas and the density of infiltration was 
estimated (per 0.24mm2) at higher magnification 
(×400). For statistical analyses, the density of CD163+ 
macrophages in the TS were dichotomized into low 
(0-36 macrophages/0.24mm2) and high infiltration 
(>36 macrophages/0.24mm2) according to the median 
(Table 1). CD68+ macrophages in the TS were also 
scored by this critical value to unify the scoring 
criteria. Similarly, the density of CD163 in the TN was 
denoted as low (0-11 macrophages/0.24mm2) and 
high (>11 macrophages/0.24mm2) according to the 
median (Table 1), and the density of CD68 in the TN 
was also assessed by this critical value. Two 
researchers (pathologists) blinded to the clinical 
information carried out the evaluation process. 
Additional immunohistochemistry was per-
formed on serial tissue sections for molecular 
sub-classification of the tumors. Primary antibodies 
against ER (clone SP1, 1:150 dilution, Zymed, San 
Francisco, CA), PR (clone SP2, 1:150 dilution, Zymed), 
and HER2 (DAKO HercepTestTM, Denmark,), Ki-67 
(clone SP6, 1:200 dilution, ThermoScientific, Fremont 
CA), EGFR (clone 31G7, 1:100 dilution, Zymed), and 
CK5/6 (clone D5/16B4, 1:100 dilution, Zymed) were 
applied according to manufacturer’s instructions. 
Interpretation and scoring of ER, PR, HER2, Ki-67, 
EGFR, and CK5/6 staining described by Cheang et al. 
[22] was adopted in our study. Basal-like breast cancer 
was defined as ER negative, PR negative, HER2 
negative, and EFGR and/or CK5/6 positive. 
Confirmatory fluorescence in situ hybridization 
(FISH) evaluation using Vysis kit (Vysis, Inc., 
Downers Grove, IL) was pursued on those tumors 
with a 2+ HER2 expression by immunohistochemistry. 
The interpretation was based up the manufacture 
guideline. 
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Statistical Analysis 
Spearman’s Rho test was used to examine 
whether the expression levels of CD68 and CD163 in 
macrophages were associated with clinicopatho-
logical characteristics. Wilcoxon Signed Ranks Test 
was performed for comparing macrophages between 
different tissue locations. Overall survival (OS) was 
measured from the date of curative surgery to the 
date of breast cancer-specific death. Recurrence-free 
survival (RFS) was measured from the date of 
curative surgery to the date of breast cancer 
recurrence, regardless of whether recurrence was 
local or regional, and/or distant metastasis. 
Kaplan-Meier analysis and long-rank tests were 
performed to identify the difference in OS and RFS 
according to CD68+ and CD163+ macrophage 
infiltration. Cox regression proportional hazards 
models were performed to estimate the hazard ratios 
(HR) for RFS and OS of BLBC according to CD68+ and 
CD163+ macrophage infiltration in univariate and 
multivariate models. A two-sided P<0.05 was 
considered significant. Statistical analysis was 
performed with SPSS 19.0 software (SPSS, IBM). 
Results 
Characterization of CD68+ and CD163+ 
macrophages in BLBC 
As shown in Fig. 2, CD68+ macrophages and 
CD163+ macrophages were present in both TS and TN 
of BLBC. We evaluated the macrophages in TS and 
TN separately and found significantly more 
macrophages infiltrated in TS than in TN (CD68: 
median 40 vs. 13; Z=-11.725, p<0.001; CD163: median 
36 vs. 11; Z=-10.665, p<0.001; Table 1 and Fig. 2). The 
ratio of TN/total (CD68: median 0.24; CD163: median 
0.24) and TS/Total (CD68: median 0.72; CD163: 
median 0.73) were also shown in Table 1. There was a 
strong correlation between CD163 and CD68 in both 
TS (rs=0.404, p<0.001) and TN (rs=0.621, p<0.001). No 
correlation was identified between the infiltration 
density of CD163+ macrophages in the TS and in the 
TN (rs=0.060, p=0.399) (Table 1), while a significant 
correlation between the infiltration density of CD68+ 
macrophages in the TS and in the TN (rs=0.275, 
p<0.001) (Table 1) was identified. 
 
 
Fig. 2. The density and distribution pattern of macrophage infiltration characterized by CD68 and CD163 immunoreactivity in the tumor nest (TN) and tumor stroma (TS) of 
BLBC. A-B Representative images of high density of CD68+ staining (A) and CD163 staining (B) in TN and TS. C-D Representative images of low density of CD68+ staining (C) 
and CD163 staining (D) in TN and TS. Scale bar, 100 μm 
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Table 1. Distribution pattern of TAMs in BLBC 
Variables Meana SEa Mediana Rangea Zb Pb rsc Pc 
CD68+ macrophage     -11.725 <0.001 0.275 <0.001 
Tumor nest 15 1.01 13 2-79     
Tumor stroma 46 2.56 40 5-197     
CD163+ 
macrophage 
    -10.665 <0.001 0.060 0.399 
Tumor nest 14 0.92 11 1-75     
Tumor stroma 42 2.09 36 3-184     
TN/total         
CD68+ macrophage 0.23 0.01 0.24 0-0.63     
CD163+ macrophage 0.25 0.01 0.24 0-0.61     
TS/Total         
CD68+ macrophage 0.72 0.01 0.72 0.38-1     
CD163+ macrophage 0.74 0.01 0.73 0.35-0.94     
a Cell count per field (cells/0.24 mm2) 
b Wilcoxon signed ranks test 
c Spearman’s Rho test 
 
Correlations of CD68+ and CD163+ 
macrophages to clinicopathological features 
High infiltrations of CD68+ macrophage and 
CD163+ macrophage in the TS were both positively 
associated with larger tumor size (rs=0.203, p=0.004; 
rs=0.284, p<0.001, respectively), higher histological 
grade (rs=0.153, p=0.030; rs=0.581, p<0.001, 
respectively), higher 5-year recurrence rate (rs=0.217, 
p=0.002; rs=0.145, p=0.041, respectively) and higher 
5-year breast cancer mortality (rs=0.215, p=0.002; 
rs=0.178, p=0.011, respectively). Higher density of 
CD163+ macrophage (rs=-0.380, p<0.001), but not 
CD68+ macrophage (rs=-0.124, p=0.080), in the TS was 
observed in tumors of younger patients. There was no 
significant association between stromal CD68+ and 
CD163+ macrophage infiltration and lymph node 
metastasis (rs=0.130, p=0.067; rs=0.029, p=0.688, 
respectively) (Table 2 and 3). In contrast, neither 
CD68+ macrophages nor CD163+ macrophages in the 
TN was found significantly correlated with any of the 
above clinicopathological features (p>0.05; Table 2 
and 3).  
Prognostic significance of CD68+ macrophages 
and CD163+ macrophages 
Univariate Cox proportional hazards regression 
analysis identified that the high density of CD68+ and 
CD163+ macrophage infiltration in TS was associated 
with poor OS (HR=2.985, p=0.005; HR=3.548, p<0.001) 
and RFS (HR=2.229, p=0.005; HR=3.975, p<0.001) 
(Table 4; Fig. 3). In contrast, there was no correlation 
between CD68+ or CD163+ macrophages in TN with 
OS (HR=0.951, p=0.870; HR=1.322, p=0.371) and RFS 
(HR=0.925, p=0.753; HR=1.496, p=0.108) (Table 4; Fig. 
3). 
Multivariate Cox proportional hazards 
regression analysis, after adjusting for patient age, 
tumor size, histological grade, lymph node stage and 
radiotherapy, proved CD163+ macrophages in TS, but 
not CD68+ macrophages, was an independent 
prognostic factor for worse OS (HR=3.427, p=0.009) 
and RFS (HR=4.304, p<0.001) (Table 5). 
 
Table 2. Correlations between CD68+ macrophages and 
clinicopathological features in BLBC by their locations 
  CD68 in TS  CD68 in TN 
Variables N High, n 
(%) 
rs P  High, n 
(%) 
rs P 
Age, years   -0.124  0.080    -0.061 0.388 
< 50 98 62(63.3)    55(56.1)   
≥50 102 52(51.0)    51(50.0)   
Tumor size, cm   0.203  0.004    0.061 0.389 
 ≤2 60 25(41.7)    29(48.3)   
 > 2 140 89(63.6)    77(55.0)   
Histological Grade 
(SBR) 
  0.153  0.030   0.037 0.608 
 Grade 1 0 0    0   
 Grade 2 94 46(48.9)    48(51.1)   
 Grade 3 106 68(64.2)    58(54.7)   
Lymph node metastasis   0.130  0.067    0.002 0.978 
 Negative 123 63(51.2)    67(54.5)   
 1 to 3 43 30(69.8)    19(44.2)   
 4 to 9 22 14(63.6)    8(36.4)   
 10 or more 12 7(58.3)    12(100)   
Recurrence (5 years)   0.217 0.002   0.041 0.568 
 No 156 80(51.3)    81(51.9)   
 Yes 44 34(77.3)    25(56.8)   
Breast cancer mortality  
(5 years) 
  0.215 0.002   0.022 0.758 
 No 162 84(51.9)    85(52.5)   
 Yes 38 30(78.9)    21(55.3)   
TS, tumor stroma; TN, tumor nest; BLBC, basal-like breast cancer. 
 
Table 3. Correlations between CD163+ macrophages and 
clinicopathological features in BLBC by their locations 
  CD163 in TS  CD163 in TN 
Variables N High, n 
(%) 
rs P  High, n 
(%) 
rs P 
Age, years   -0.380 <0.001   -0.100 0.159 
< 50 98 68(69.4)    54(55.1)   
≥50 102 32(31.4)    46(45.1)   
Tumor size, cm   0.284 <0.001   0.022 0.759 
 ≤2 60 17(28.3)    29(48.3)   
 > 2 140 83(59.3)    71(50.7)   
Histological Grade 
(SBR) 
  0.581 <0.001   -0.020 0.778 
 Grade 1 0 0    0   
 Grade 2 94 18(19.1)    48(51.1)   
 Grade 3 106 82(77.4)    52(49.1)   
Lymph node metastasis   0.029 0.688   0.011  0.872 
 Negative 123 58(47.2)    62(50.4)   
 1 to 3 43 29(67.4)    19(44.2)   
 4to 9 22 8(36.4)    11(50.0)   
 10 or more 12 5(41.7)    8(66.7)   
Recurrence (5 years)   0.145 0.041   0.072 0.308 
 No 156 72(46.2)    75(48.1)   
 Yes 44 28(63.6)    25(56.8)   
Breast cancer mortality  
(5 years) 
  0.178 0.011   0.051 0.473 
 No 162 74(45.7)    79(48.8)   
 Yes 38 26(68.4)    21(55.3)   
TS, tumor stroma; TN, tumor nest; BLBC, basal-like breast cancer. 
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Fig. 3. RFS and OS curves based on macrophage properties. A–D Recurrence-free survival and Overall survival curves by CD68-positive macrophage infiltration into the tumor 
nest (A, C) and stroma (B, D). E–H Overall survival curves by CD163-positive M2 macrophage infiltration into the tumor nest (E, G) and stroma (F, H). 
 
Table 4. Univariate Cox regression analyses for RFS and OS of 
BLBC 
Variables OS  RFS 
 HR 95%CI P   HR 95%CI P  
Age (<50 vs.≥50) 1.937 0.277-0.973 0.038  1.472 0.401-1.149 0.150 
Tumor size, cm (≤2 vs. >2) 4.999 1.782-14.023 0.002  4.314 2.055-9.054 <0.001 
Histological Grade (II vs. 
III) 
1.105 0.599-2.040 0.749  1.235 0.753-2.026 0.402 
Lymph node stage (N0 vs. 
N1-3) 
1.932 1.490-2.504 <0.001  1.929 1.573-2.366 <0.001 
Radiotherapy (no vs. yes) 3.606 2.043-6.364 <0.001  5.755 3.217-10.294 0.000 
CD68+ in TS (low vs. high) 2.985 1.381-6.449 0.005  2.229 1.269-3.914 0.005 
CD163+ in TS (low vs. 
high) 
3.548 1.697-7.417 <0.001  3.975 2.200-7.180 <0.001 
CD68+ in TN (low vs. high) 0.951 0.519-1.742 0.870  0.925 0.571-1.500 0.753 
CD163+ in TN (low vs. 
high) 
1.322 0.717-2.436 0.371  1.496 0.916-2.445 0.108 
BLBC, basal-like breast cancer; TS, tumor stroma; TN, tumor nest; OS: overall 
survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval. 
 
Table 5. Multivariate Cox regression analyses for RFS and OS of 
BLBC 
Variables OS  RFS 
 HR 95%CI P   HR 95%CI P  
Age (<50 vs.≥50) 2.463 0.184-0.897 0.026  2.032 0.244-0.991 0.047 
Tumor size, cm (≤2 vs. >2) 3.020 1.030-8.854 0.044  2.581 1.192-5.588 0.016 
Histological Grade (II vs. III) 1.435 0.647-3.180 0.374  1.367 0.722-2.588 0.338 
Lymph node stage (N0 vs. 
N1-3) 
1.748 1.311-2.331 <0.001  1.836 1.468-2.297 <0.001 
Radiotherapy (no vs. yes) 1.328 0.938-1.882 0.110  1.190 0.906-1.564 0.212 
CD68+ in TS (low vs. high) 1.850 0.796-4.298 0.153  1.250 0.666-2.345 0.487 
CD163+ in TS (low vs. high) 3.427 1.368-8.587 0.009  4.304 1.994-9.286 <0.001 
BLBC, basal-like breast cancer; TS, tumor stroma; OS: overall survival; RFS: 
recurrence-free survival; HR: hazard ratio; CI: confidence interval. 
 
Discussion 
Macrophages are heterogeneous subsets with 
different functions. CD68 has been used to recognize 
tumoricidal M1 and pro-tumoral M2 macrophages. 
Even though multiple clinical studies had evidenced 
that CD68+ macrophage positively associated with 
high vascularity and nodal metastasis and negatively 
correlated with RFS and OS in breast cancer, as a 
pan-macrophage marker, CD68 was found not an 
independent predictor of OS in some multivariate 
analyses [14, 15, 17]. A prior study using tissue 
microarrays (TMAs) with a large sample size suggests 
that overall numbers of CD68+ macrophages are not 
related to prognosis in breast cancer [15]. These 
results demand further investigation to identify the 
subset of TAMs that may service as the 
prognosis-related biomarkers. Meanwhile, CD163, a 
highly specific biomarker for M2 macrophages [29, 
32], was found to be closely correlated with 
unfavorable clinicopathological characters in some 
study.[20] It has been recently found that BLBC hosts 
more TAMs infiltration, particularly the CD163+ cells, 
than other types of breast cancers [20]. However, the 
study with a small number of BLBC cases did not 
explore the prognostic significance of CD68+ and 
CD163+ macrophages in BLBC. We therefore 
undertook the study to evaluate the infiltration of 
stromal and intraepithelial CD68+ macrophages along 
with the identification of CD163+ macrophages to 
assess their prognostic value in a larger BLBC cohort. 
In addition, TAMs in different intratumoral regions 
are subsets with distinct molecular and functional 
features, and thus may exhibit different prognostic 
values. Unfortunately, limited studies have 
considered the locations in the evaluation of clinical 
significance. Although three studies (two by marker 
of CD68 [15, 33] and one by markers of CD68 and 
CD163 [20]) in human breast cancer have included the 
locations of TAMs, two of which used the TMA 
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samples to put it into practice [15, 20]. We used full 
block-face tissue sections in the study to overcome the 
limitation of core materials that only contain small 
volume of tumor tissue may suffer from bias in the 
assessment of TAMs due to tumor heterogeneity. Full 
block-face tissue sections allow the selection of tumor 
areas with abundant TAMs for accurate scoring in 
tumor nest and in tumor stroma separately. 
In this cohort of BLBC, CD68+ or CD163+ 
macrophages in TN was not found to be correlated 
with any of the clinicopathological features, OS or 
RFS. Medrek et al. recently also found no correlations 
between clinicopathological features and CD68+ or 
CD163+ macrophage infiltrates in tumor nest, and the 
same relationship with RFS and OS was also noted 
[20]. Mahmoud et al. reported that intratumoural 
CD68+ macrophage did not correlate with breast 
cancer-specific survival [15]. Although the methods 
and molecular subtypes of breast cancer patients were 
different in these studies, the results suggest that the 
TAMs infiltrates into tumor nest is not an important 
prognostic factor for patient outcome. 
TAM promotes tumor progression through 
several mechanisms [37]. In contrast to TN, the study 
found that increased CD68+ or CD163+ macrophages 
in TS were correlated with larger tumor size, higher 
histological grade, and worse RFS and OS. It 
suggested that TAMs may affect the prognosis of 
BLBC mainly through modulating the immune 
response by contacting with tumor-infiltrating 
lymphocytes in TS, rather than through the direct 
interaction between macrophages and cancer cells in 
TN, such as phagocytosis of cancer cells. However, 
the specific underlying mechanisms need further 
study. It is worthy of notice that although univariate 
analysis identified the total TAM infiltrates in TS was 
associated with poor RFS and OS in BLBC, 
multivariate analysis only proved CD163+ 
macrophages in TS was an independent predictor of 
RFS and OS. We also got similar conclusions in 
multivariate Cox regression analyses using 
continuous variables, one-quarter and median as the 
cutoffs, i.e., CD163+ macrophages in TS was an 
independent prognostic factor for worse OS and RFS 
(Supplementary Table 1). It indicates that in contrast 
to the pan-macrophage marker CD68, macrophages 
expressing the anti-inflammatory CD163 marker (M2 
macrophages) are probably the effect TAMs that 
facilitate the poor prognosis of BLBC and serve as an 
independent prognostic predictor. 
A number of potential macrophage-centred 
therapeutic strategies are being explored [37]. Either 
manipulating TAMs localization at tumor sites, or 
targeting the signal pathways affecting TAMs 
polarization and functions is proved to improve the 
outcomes of breast cancer [38]. The pro-tumor M2 
macrophage, recognized by CD163, is reversible [39, 
40]. Duluc et al. used INF-γ to reverse the 
immunosuppressive and pro-tumoral foundations 
and prevent the generation of M2 macrophage [41]. 
Similar to the result, Guiducci et al. activated TLR9 by 
its ligand CpG, along with antibody to IL-10, and 
switched TAMs from an M2 macrophage to an M1 
macrophage [42]. And classically activated M1 
macrophage can kill cancer cells and induce 
tumor-destructive reaction [43]. Therefore, blocking 
key molecular determinants of macrophage 
polarization may result in reorientation of 
macrophage polarization and activate the anti-tumor 
activity [39, 44, 45]. In a preclinical glioma model, a 
small molecule agent BZL945 (CSF-1R inhibitor) 
improved the survival by ‘re-education’ of 
macrophages from a protumor M2-like phenotype to 
an antitumor M1-like type instead of TAM number 
depletion [46]. Although TAM-centered strategies 
have not been yet introduced in clinical practice in 
terms of effectiveness and tolerability in breast cancer 
patients, reducing number or reeducating of TAM 
seems to be a promising strategy and should be 
further investigated due to its clinical significance in 
BLBC. 
There are limitations in the study. Although 
CD163 was regarded as a highly special M2 macro-
phage marker, it can also be expressed by monocyte- 
derived dendritic cells (MDCs) [47]. Medrek C et al. 
observed some CD163+ areas lacked CD68 expression. 
They attributed this to a CD163-expressing subset of 
immature myeloid derived suppressor cells with 
prognostic impact although no direct data was 
available [20]. Thus, we cannot exclude MDCs cells or 
myeloid derived cells expressing CD163, which could 
have impact on the poor prognosis trigged by CD163+ 
macrophage in BLBC. It is warranting to further 
clarify the phenotype of TAMs and the significant 
impact of M1/M2 macrophage ratio on the clinical 
course of BLBC patients. Few specific markers are so 
far available, and therefore there is still an urgent 
need to identify markers specific for M1/M2 
macrophage. Some other TAM-related biomarkers 
that have been explored include CD206, VEGF, HIFs, 
TFL, PCNA and CCL18 [4]. Further investigation to 
identify their roles in sub-classifying TAMs into 
different prognosis-related biological groups will be 
meaningful and will be one of the focuses of our 
future studies.  
Conclusion 
This study identified that infiltration of CD68+ or 
CD163+ macrophages in TS, not the TN, is associated 
with the clinicopathological features of BLBC and 
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worse prognosis of patients. CD163+ macrophages in 
TS, instead of CD68+ macrophage, is proven to an 
independent risk factor for worse RFS and OS. TAMs 
signature is a promising therapeutic target in BLBC. 
However, further work is still warranting to validate 
the findings. 
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